Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Britain Courts Anthropic Amid US Defense Department Dispute 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Apple Turns 50: From Garage Startup to AI Crossroads 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SAN DIEGO, Feb. 21, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its fourth quarter and full year 2016 financial and operating results after the close of U.S. financial markets on Tuesday, February 28, 2017. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | |
| Date: | February 28, 2017 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 73756754 |
| Via web: | www.traconpharma.com; “Events and Presentation” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
